SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

Search

Valneva SE

Deschisă

3.21 -0.31

Rezumat

Modificarea prețului

24h

Curent

Minim

3.09

Maxim

3.25

Indicatori cheie

By Trading Economics

Venit

-28M

-37M

Vânzări

7.1M

53M

EPS

-0.25

Marjă de profit

-69.865

Angajați

713

EBITDA

-19M

-26M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+78.13% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-64M

513M

Deschiderea anterioară

3.52

Închiderea anterioară

3.21

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Valneva SE Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 nov. 2024, 10:28 UTC

Principalele dinamici ale pieței

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

3 sept. 2024, 10:28 UTC

Câștiguri

Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data

15 nov. 2024, 10:34 UTC

Market Talk

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

3 sept. 2024, 10:31 UTC

Market Talk

Valneva Shares Gain on Positive Vaccine News -- Market Talk

Comparație

Modificare preț

Valneva SE Așteptări

Obiectiv de preț

By TipRanks

78.13% sus

Prognoză pe 12 luni

Medie 5.7 EUR  78.13%

Maxim 8.1 EUR

Minim 3.3 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruValneva SE - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

1

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

3.2 / 3.32Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.